Measuring the side effects of taxane therapy in oncology

Cancer chemotherapy with some of the taxane class of agents can be associated with significant neurotoxicity, arthralgias, myalgias, and skin changes that may offset the therapeutic benefits of taxane use.

[1]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[2]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[3]  P. Schiff,et al.  Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[5]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[6]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Tulsky,et al.  Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. , 1995, Lung cancer.

[8]  P. Vrignaud,et al.  Preclinical evaluation of docetaxel (Taxotere). , 1995, Seminars in oncology.

[9]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[10]  J. Verweij,et al.  Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. , 1995, Cancer treatment reviews.

[11]  D. Cella,et al.  Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. , 1998, Statistics in medicine.

[12]  R. Tankanow.  Docetaxel: a taxoid for the treatment of metastatic breast cancer. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[13]  D. Cella,et al.  Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. , 1998, Statistics in medicine.

[14]  W. Tierney,et al.  Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. , 1999, Journal of clinical epidemiology.

[15]  H. Choy,et al.  Patterns of practice survey for nonsmall cell lung carcinoma in the U.S. , 2000, Cancer.

[16]  W. Eiermann,et al.  Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Baker,et al.  Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Dimopoulos,et al.  Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Michael J Schell,et al.  Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Cella,et al.  What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. , 2002, Journal of clinical epidemiology.

[21]  N. Robert,et al.  Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Richie.  Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. , 2003, The Journal of urology.

[23]  L. Deangelis,et al.  Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing , 1997, Journal of Neuro-Oncology.